ArriVent BioPharma, Inc. Common Stock

NASDAQ:AVBP

Biotechnology

Healthcare
$10.90 +1.40%

+$0.44 today

Market cap
$563.78M
Beta
1.42
P/E (TTM)
-9.8
EPS (TTM)
-$3.22
52W Low $16.10High $33.62

Volume 2.70M

Average 0.50M

AVBP Sales of Investments

Cash received from selling or redeeming investments.

ArriVent BioPharma, Inc. Common StockNASDAQ: AVBP

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments grows, but more slowly than its trailing trend

Q1 FY2026 sales of investments of $67.97M rose 45.7% year over year, behind the +378.2% change in trailing-twelve-month sales of investments. Sequentially, it fell 15.0% from the prior quarter.

Context

  • Sales of investments increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +45.7% toward the trailing-twelve-month pace of +378.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$67.97M-15.0% QoQ
Last fiscal yearDec 2025
$201.71M+11772.0% YoY
LTMMar 2026
$223.03M+378.2% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+45.7%——
1 year+11772.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
201.71M USD
Year-over-year change
+11772.0%

Sales of Investments vs competitors

How AVBP compares with its peers on the latest reported figures

  • AVBP's LTM Mar 2026 sales of investments of $223.03M is the 5th largest of the 11 companies compared; the peer median is $141.76M.
  • Its year-over-year change of +378.2% is the highest of 11, against a peer median of -20.0%.
AVBP Competitors Peer median
Sales of Investments for AVBP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EXELExelixis, Inc.LTM Jul 2026$805.24M -19.9%-1.3%33.1%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$656.41M -13.2%+44.4%291.4%
ERASErasca, Inc.LTM Sep 2026$282.43M -0.5%+48.4%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$225M -27.4%+24.5%—
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$223.03M +378.2%——
TYRATyra Biosciences, Inc.LTM Mar 2026$177M +1.3%——
NUVBNuvation Bio Inc.LTM Jun 2026$139.19M -130.9%-7.5%81.9%
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$106.52M -20.1%+1.5%—
PBYIPuma Biotechnology, Inc.LTM Mar 2026$85.26M +33.1%+56.1%37.5%
ZLABZai Lab LimitedLTM Jun 2026$0 -100.0%-22.3%0.0%
HCMHUTCHMED (China) LimitedLTM Jun 2025$0 -100.0%+21.8%0.0%
Peer median (excluding AVBP) $141.76M-20.0%+21.8%35.3%

Competitors are the stored peer set for AVBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(51.61M)(36.91M)(69.33M)(80.49M)(166.31M)
Depreciation & Amortization0000(3.03M)
Deferred Income Tax00000
Stock-Based Compensation66.67K424K895K3.21M12.52M
Change in Working Capital(3.94M)(7.15M)12.6M7.07M(3.77M)
Accounts Receivables00000
Inventory00000
Accounts Payables293K2.8M1.38M(751K)2.14M
Other Working Capital(4.23M)(9.95M)11.22M7.82M(5.92M)
Other Non-Cash Items42.96M0000
Operating Cash Flow(12.59M)(43.63M)(55.84M)(70.21M)(160.59M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments00(25M)(194.16M)(272.93M)
Sales of Investments0025M1.7M201.71M
Other Investing Activities(40M)0000
Investing Cash Flow(40M)00(192.47M)(71.23M)
Debt Repayment00000
Common Stock Issued89.87M2K354K185.95M202.63M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities015K(2.06M)631K(70K)
Financing Cash Flow89.87M169.72M42.86M186.58M203.06M
Effect of Forex Changes00000
Net Change in Cash37.28M126.09M(12.98M)(76.1M)(28.75M)
Free Cash Flow(12.59M)(43.63M)(55.84M)(70.21M)(160.59M)

ArriVent BioPharma, Inc. Common Stock

NASDAQ:AVBP

Intrinsic Alpha fair value

Locked

Current Price

$10.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.